Benefits of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

References

• Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology71, 129–135 (2008).
   PubMed Web of Science ®Google Scholar
• Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology68, 326–337 (2007).
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin. Neurol.28, 17–28 (2008).
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet359, 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology58, 169–178 (2002).
   PubMed Web of Science ®Google Scholar
• Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology68, S22–S31; discussion S43–S54 (2007).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain129, 606–616 (2006).
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol.58, 1602–1606 (2001).
   PubMed Web of Science ®Google Scholar
• NMSS. Disease management consensus statement – treatment recommendations for physicians. US Neurology Review, Touch Briefings, London, UK, 47–50 (2005).
   Google Scholar
• Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann. Rheum. Dis.58(Suppl. 1), I82–I85 (1999).
   PubMed Web of Science ®Google Scholar
• Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J. Neurol.255(Suppl. 1), 26–36 (2008).
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med.317, 408–414 (1987).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. Neurology45, 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology50, 701–708 (1998).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol.49, 290–297 (2001).
   PubMed Web of Science ®Google Scholar
• Ge Y, Grossman RI, Udupa JK et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology54, 813–817 (2000).
   PubMed Web of Science ®Google Scholar
• Tintore M. Early MS treatment. Int. MS J.14, 5–10 (2007).
   PubMedGoogle Scholar
• Comi G. Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndromes (CIS). American Academy of Neurology 60th Annual Meeting. Chicago, IL, USA, LBS.003 (2008).
   Google Scholar
• Boneschi FM, Rovaris M, Johnson KP et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult. Scler.9, 349–355 (2003).
   PubMed Web of Science ®Google Scholar
• Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev.4, CD004678 (2003).
   Google Scholar
• Mikol DD, Barkhof F, Chang P et al. Comparison of subcutaneous interferon β-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol.7, 903–914 (2008).
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky L, Skurnick S et al. Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology (2009) (Epub ahead of print).
   Google Scholar
• O’Connor P, Arnason B, Comi G et al. Inteferon β-1b 500mcg, interferon β-1b 250 mcg and glatiramer acetate: primary outcomes of the Bferon/Bseron Efficacy Yielding Outcomes of a New Dose study. Presented at: American Academy of Neurology 60th Annual Meeting. Chicago, IL, USA, LBS.004 (2008).
   Google Scholar
• Wolinsky JS. The use of glatiramer acetate in the treatment of multiple sclerosis. Adv. Neurol.98, 273–292 (2006).
   PubMedGoogle Scholar
• Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can. J. Neurol. Sci.31, 58–63 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson KP. Control of multiple sclerosis relapses with immunomodulating agents. J. Neurol. Sci.256(Suppl. 1), S23–S28 (2007).
   Google Scholar
• Rauschka H, Farina C, Sator P, Gudek S, Breier F, Schmidbauer M. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology64, 1481–1482 (2005).
   PubMed Web of Science ®Google Scholar
• Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult. Scler.12, 309–320 (2006).
   PubMed Web of Science ®Google Scholar
• Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon β-1b (betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J. Neurol. Sci.197, 51–55 (2002).
   PubMed Web of Science ®Google Scholar
• Rolak LA, Brown S. Headaches and multiple sclerosis: a clinical study and review of the literature. J. Neurol.237, 300–302 (1990).
   PubMed Web of Science ®Google Scholar
• Johnson SL. The concept of fatigue in multiple sclerosis. J. Neurosci. Nurs.40, 72–77 (2008).
   PubMed Web of Science ®Google Scholar
• Pollmann W, Erasmus LP, Feneberg W, Then Bergh F, Straube A. Interferon β but not glatiramer acetate therapy aggravates headaches in MS. Neurology59, 636–639 (2002).
   PubMed Web of Science ®Google Scholar
• Pollmann W, Erasmus LP, Feneberg W, Straube A. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Neurology66, 275–277 (2006).
   PubMed Web of Science ®Google Scholar
• Metz LM, Patten SB, Archibald CJ et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J. Neurol. Neurosurg. Psychiatr.75, 1045–1047 (2004).
   PubMed Web of Science ®Google Scholar
• Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual. Life Outcomes6, 100 (2008).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon β: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology68, 977–984 (2007).
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Brenner T, Abramsky O, Aharoni R, Sela M, Arnon R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult. Scler.9, 592–599 (2003).
   PubMed Web of Science ®Google Scholar
• Brenner T, Arnon R, Sela M et al. Humoral and cellular immune response to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J. Neuroimmunol.115, 152–160 (2001).
   PubMed Web of Science ®Google Scholar
• Hopman WM, Coo H, Edgar CM, McBride EV, Day AG, Brunet DG. Factors associated with health-related quality of life in multiple sclerosis. Can. J. Neurol. Sci.34, 160–166 (2007).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology66, 1696–1702 (2006).
   PubMed Web of Science ®Google Scholar
• Miller A, Dishon S. Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status. Qual. Life Res.15, 259–271 (2006).
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler.6, 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatr.77, 918–926 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Oleen-Burkey M, Denney D. Quality of life in multiple sclerosis: relationship between EDSS and health status. Presented at: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Prague, Czech Republic, 866 (2007).
   Google Scholar
• Oleen-Burkey M, Johnson K, Hadjimichael O, Vollmer T. Improved quality of life among patients treated long-term with glatiramer acetate. Presented at: 22nd Consortim of Multiple Sclerosis Centers Annual Meeting. Denver, CO, USA, S56 (2008).
   Google Scholar
• Dennett S, Castelli-Haley J, Oleen-Burkey M. The impact of multiple sclerosis on patient employment: a review of the medical literature. J. Health Productivity,12–18 (2007).
   Google Scholar
• Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work27, 143–151 (2006).
   PubMedGoogle Scholar
• Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual. Life Outcomes6, 67 (2008).
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, Johnson KP. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult. Scler.7, 33–41 (2001).
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G. Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology59, 1284–1286 (2002).
   PubMed Web of Science ®Google Scholar
• Rovaris M, Comi G, Rocca MA et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult. Scler.13, 502–508 (2007).
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Sardanelli F, Parodi RC et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology50, 1127–1133 (1998).
   PubMed Web of Science ®Google Scholar
• Rovaris M, Codella M, Moiola L et al. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology59, 1429–1432 (2002).
   PubMed Web of Science ®Google Scholar
• Khan O, Shen Y, Caon C et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult. Scler.11, 646–651 (2005).
   PubMed Web of Science ®Google Scholar
• Khan O, Shen Y, Bao F et al. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis. J. Neuroimaging18, 314–319 (2008).
   PubMed Web of Science ®Google Scholar
• Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex), IFNβ-1b (Bseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. Mult. Scler.7, 349–353 (2001).
   PubMed Web of Science ®Google Scholar
• Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with β interferons or glatiramer acetate (Copaxone). Eur. J. Neurol.12, 425–431 (2005).
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Oleen-Burkey MK, Lage MJ, Johnson KP. Glatiramer acetate versus interferon β-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients. Adv. Ther.25, 658–673 (2008).
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus β interferon therapy among patients with multiple sclerosis in a managed care population. J. Manag. Care Pharm.8, 469–476 (2002).
   PubMedGoogle Scholar
• Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J. Manag. Care Pharm.13, 44–52 (2007).
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson K. Glatiramer acetate versus interferon β-1b for subcutaneous administration: a comparison of outcomes among multiple sclerosis patients. Presented at: International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress. Athens, Greece, PND4 (2008).
   Google Scholar
• Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson K. Glatiramer acetate versus interferon β-1a for intramuscular administration: a comparison of outcomes among multiple sclerosis patients. Presented at: International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress. Athens, Greece, PND6 (2008).
   Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost–effectiveness of interferon β-1a, interferon β-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health7, 554–568 (2004).
   PubMed Web of Science ®Google Scholar
• Chilcott J, McCabe C, Tappenden P et al. Modelling the cost effectivenes of interferon β and glatiramer acetate in the management of multiple sclerosis. BMJ326, 522 (2003).
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost–effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J. Manag. Care Pharm.13, 245–261 (2007).
   PubMed Web of Science ®Google Scholar
• Graham J, Earnshaw S, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost–effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Presented at: International Society for Pharmacoeconomics and Outcomes Research 10th Annual European Congress. Dublin, Ireland, 20–23 October 2007.
   Google Scholar